Quest Diagnostics Inc Net Income (Loss) Available to Common Stockholders, Diluted
Quest Diagnostics Inc (DGX) reported Net Income (Loss) Available to Common Stockholders, Diluted of $319.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-07-23
- Quest Diagnostics Inc net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $319.00M, a 13.52% increase year-over-year.
- Quest Diagnostics Inc net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $251.00M, a 14.61% increase year-over-year.
- Quest Diagnostics Inc net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was $243.00M, a 8.00% increase year-over-year.
- Quest Diagnostics Inc net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was $281.00M, a 23.25% increase year-over-year.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month |
|---|---|---|---|
| 2026-06-30 | $319.00M 10-Q · filed 2026-07-23 | $570.00M 10-Q · filed 2026-07-23 | |
| 2026-03-31 | $251.00M 10-Q · filed 2026-04-22 | ||
| 2025-09-30 | $243.00M 10-Q · filed 2025-10-21 | $524.00M derived: sum of 2 quarters · filed 2026-07-23 | $743.00M 10-Q · filed 2025-10-21 |
| 2025-06-30 | $281.00M 10-Q · filed 2026-07-23 | $500.00M 10-Q · filed 2026-07-23 | |
| 2025-03-31 | $219.00M 10-Q · filed 2026-04-22 | ||
| 2024-09-30 | $225.00M 10-Q · filed 2025-10-21 | $453.00M derived: sum of 2 quarters · filed 2025-10-21 | $646.00M 10-Q · filed 2025-10-21 |
| 2024-06-30 | $228.00M 10-Q · filed 2025-07-23 | $421.00M 10-Q · filed 2025-07-23 | |
| 2024-03-31 | $193.00M 10-Q · filed 2025-04-23 | ||
| 2023-09-30 | $223.00M 10-Q · filed 2024-10-23 | $457.00M derived: sum of 2 quarters · filed 2024-10-23 | $658.00M 10-Q · filed 2024-10-23 |
| 2023-06-30 | $234.00M 10-Q · filed 2024-07-24 | $435.00M 10-Q · filed 2024-07-24 | |
| 2023-03-31 | $201.00M 10-Q · filed 2024-04-24 | ||
| 2022-09-30 | $254.00M 10-Q · filed 2023-10-25 | $487.00M derived: sum of 2 quarters · filed 2023-10-25 | $841.00M 10-Q · filed 2023-10-25 |
| 2022-06-30 | $233.00M 10-Q · filed 2023-07-27 | $587.00M 10-Q · filed 2023-07-27 | |
| 2022-03-31 | $354.00M 10-Q · filed 2023-04-28 | ||
| 2021-09-30 | $503.00M 10-Q · filed 2022-10-21 | $1.13B derived: sum of 2 quarters · filed 2022-10-21 | $1.60B 10-Q · filed 2022-10-21 |
| 2021-06-30 | $628.00M 10-Q · filed 2022-07-22 | $1.10B 10-Q · filed 2022-07-22 | |
| 2021-03-31 | $468.00M 10-Q · filed 2022-04-22 | ||
| 2020-09-30 | $566.00M 10-Q · filed 2021-10-22 | $750.00M derived: sum of 2 quarters · filed 2021-10-22 | $849.00M 10-Q · filed 2021-10-22 |
| 2020-06-30 | $184.00M 10-Q · filed 2021-07-23 | $283.00M 10-Q · filed 2021-07-23 | |
| 2020-03-31 | $99.00M 10-Q · filed 2021-04-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |